newsfilter
← Earnings
Earnings Releases·

Monopar Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss for Q3 2026 widened to $6.2 million ($0.72 per share) from $3.4 million ($0.48 per share) in Q3 2025, driven by a $1.8 million increase in R&D expenses and a $1.5 million rise in G&A expenses.
  • Cash, cash equivalents, and investments totaled $129.4 million as of September 30, 2026, providing a runway to support operations through at least March 31, 2028.
  • The company is on track to complete the NDA submission for ALXN1840 within the next several weeks following FDA authorization for rolling submission on July 22, 2026.
  • The Phase 3 FoCus trial met its primary endpoint with rapid and sustained copper mobilization, and the company appointed Dr. Jeffrey D. Kent as Executive Vice President, Head of Medical Affairs, to prepare for potential commercialization.
Company
MONOPAR THERAPEUTICS
Sector
Healthcare
Industry
Biotechnology